沙格列汀对2型糖尿病伴正常体重的代谢性肥胖患者体脂成分的影响

发布时间：2018-03-17 06:36

本文选题：糖尿病　切入点：型　出处：《中国糖尿病杂志》2016年08期 　论文类型：期刊论文

【摘要】：目的评估沙格列汀联合二甲双胍治疗T2DM伴正常体重代谢性肥胖(MONW)患者的有效性,以及对体脂成分的影响。方法选取单用二甲双胍12周但血糖控制不佳的、18.5≤BMI24kg/m~2的T2DM患者197例,且均符合MONW诊断标准。按照随机数字法将研究对象分为沙格列汀组100例和格列吡嗪组97例。两组均联合二甲双胍治疗12周,观察体脂率(BF),糖脂代谢指标及炎症指标的变化。结果两组HbA_1c较治疗前降低[沙格列汀(8.37±0.75)%vs(7.25±0.62)%,格列吡嗪(8.42±0.78)%vs(7.27±0.72)%,P0.05];沙格列汀组低血糖发生率低于格列吡嗪组(3.0%vs29.9%,P0.01)。沙格列汀组WC[男(85.84±4.07)vs(84.08±4.53)cm,女(81.53±5.93)vs(79.09±4.91)cm]和BF[男(28.71±4.22)%vs(27.47±5.66)%,女(37.18±6.52)%vs(36.06±6.30)%]较治疗前降低(P0.05);沙格列汀组治疗后WC[男(86.94±4.20)vs(84.08±4.53)cm,女(83.48±5.51)vs(79.09±4.91)cm]和BF[男(30.70±5.72)%vs(27.47±5.66)%,女(39.36±7.23)%vs(36.06±6.30)%]均较格列吡嗪组降低(P0.01)。沙格列汀组胰岛素抵抗指数(HOMA-IR)[3.25(1.68~6.11)vs 2.88(1.48~5.52)]及高敏C反应蛋白(hsC-RP)[1.67(0.51~3.97)vs 1.51(0.44~4.63)mg/L]较治疗前降低(P0.05)。结论沙格列汀在有效控制T2DM伴MONW患者血糖的同时,可降低其BF,减轻IR,改善患者慢性炎症状态。
[Abstract]:Objective to evaluate the efficacy of salgletine combined with metformin in the treatment of T2DM with normal body weight metabolic obesity and its effect on body fat composition. Methods 197 patients with T2DM who received metformin alone for 12 weeks but whose blood glucose was not well controlled were selected. In accordance with the MONW diagnostic criteria, the subjects were divided into two groups according to the random number method: one hundred cases in the salgletine group and 97 cases in the glipizide group. Both groups were treated with metformin for 12 weeks. Results compared with before treatment, HbA_1c in the two groups was lower than that before treatment [salgletine 8.37 卤0.75 vs 7.25 卤0.62C, glipizide 8.42 卤0.78 vs 7.27 卤0.72P 0.05], the incidence of hypoglycemia in the salgletine group was lower than that in the glipizide group 3.0vs29.9P0.01.The WC of the salgletine group was 85.84 卤4.07vs84.08 卤4.53cm-1, and the incidence of hypoglycemia in the salgletine group was lower than that in the glipizide group. After treatment, female patients (81.53 卤5.93v / s 79.09 卤4.91cm) and BF [male 28.71 卤4.22vsl = 27.47 卤5.66cm, female = 37.18 卤6.52vsl 36.06 卤6.30g] decreased P0.055g compared with those before treatment in the salgletine group (86.94 卤4.20 vs 84.08 卤4.53 cm, 83.48 卤5.51 vs 79.09 卤4.91cm) and BF [30.70 卤5.72vsl 27.47 卤5.66g / g, 39.36 卤7.23svv06 卤6.306.30%] compared with the Gelatin group (P < 0.01). Conclusion Saglitine can effectively control blood glucose in patients with T2DM with MONW. Can reduce its BF, alleviate IR, improve patient chronic inflammation condition.
【作者单位】：安徽医科大学附属省立医院安徽省立医院内分泌科;
【基金】：安徽省卫生厅医学科研课题项目(13zc003)
【分类号】：R587.1;R589.2

【相似文献】